Cracked gaskets and rust-like residues trigger FDA warning letter to Alchymars - BioSpace
FDA issued a warning letter to Alchymars for cracked gaskets and rust-like residues, indicating cGMP violations. This signals increased FDA scrutiny on manufacturing facilities, potentially leading to enforcement actions for non-compliance.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; FDA may conduct inspections or issue similar warning letters if deficiencies are found.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA warning letter to Alchymars highlights cGMP deficiencies (cracked gaskets, rust residues) that can lead to product contamination and regulatory action.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities
What you must do
Review and remediate facility equipment and cleanliness to prevent similar observations; ensure cGMP compliance in all manufacturing areas.
Deadline
Immediately; FDA may conduct inspections or issue similar warning letters if deficiencies are found.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)